Updated 9/12/2023. The results chart includes audits where the findings have been finalized. Remaining audits are still under review. Information on Corrective Action Plans and Sanctions will be updated once approved by HRSA. HRSA recommends covered entities do not contact audited manufacturers regarding sanctions until a corrective action plan has been approved by HRSA and posted on this website.
| Manufacturer Sort descending | Labeler Codes Reviewed | State | OPA Findings | Sanction | Corrective Action Status |
|---|---|---|---|---|---|
| Almaject Inc. |
72611 47781 52427 43199 49909 13913 |
NJ |
Almaject did not submit quarterly pricing data in 340B OPAIS |
None |
CAP implemented Audit closure date: October 27, 2022 |
KVK-Tech, Inc.Contact InformationSr. Manager Customer Service/Accounting |
10702 | PA |
Incorrect 340B OPAIS record KVK-Tech failed to refund covered entities for charges that were more than the 340B ceiling price. |
Repayment to covered entities |
CAP implemented Audit closure date: |
| Mitsubishi Tanabe Pharma America, Inc. | 70510 | NJ |
No adverse findings |
None |
N/A |
Unichem Pharmaceuticals (USA), Inc.Contact InformationPrescription Analytics, Inc. |
29300 | NJ |
Incorrect 340B OPAIS record. Unichem did not determine the difference between new drug price estimates and actual 340B ceiling price and offer a refund. |
Repayment to covered entities |
CAP implemented Audit closure date: November 17, 2022 |
Vistapharm, Inc.Contact InformationFinance Manager |
66689 | NJ |
Incorrect 340B OPAIS record. Vistapharm charged more than the 340B ceiling price. |
Repayment to covered entities |
CAP implemented Audit closure date: August 21, 2023 |